The OHSU Knight Cancer Institute is a world leader in treating leukemia. Our director, Dr. Brian Druker, is an internationally recognized pioneer in precision cancer medicine. Dr. Druker played a central role in developing Gleevec, a daily pill for chronic myelogenous leukemia (CML) that has saved tens of thousands of lives. Now he is helping lead Beat AML, a major effort to find better treatments for acute myeloid leukemia.
Every Knight Cancer employee is expected to embody our guiding principles:
One senior research assistant position is available for a motivated candidate to join the Zhang laboratory in the Division of Oncological Science within the Knight Cancer Institute at Oregon Health & Science University (OHSU). The Division of Oncological Science is a collaborative and multidisciplinary division with a broad range of expertise and well established research programs in the following four disciplines: cancer system biology, medicinal medicine, cancer data science, and cancer population science.
This position will assist in research to characterize common chromosome and copy number deletions observed in leukemia patients. The overall goal of this project is to understand how one copy deletion of tumor suppressor genes predisposes to leukemia development and how could we use the leukemia specific vulnerabilities, including the haploinsufficient phenotype observed in patients with chromosome and copy number deletions to develop synthetic lethal therapeutics.
The Zhang is highly invested in mentoring individuals in the group both scientifically and professionally and promoting personal growth at work.
Apply online. Please be sure to upload a Cover Letter and Resume/CV.